The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan
Open accessAbstract
Purpose: The combination of a vascular endothelial growth factor (VEGF) –neutralizing antibody, bevacizumab, and irinotecan is associated with high radiographic response rates and improved survival outcomes in patients with recurrent malignant gliomas. The aim of these retrospective studies was to evaluate tumor vascularity and expression of components of the VEGF pathway and hypoxic responses as predictive markers for radiographic response and survival benefit from the bevacizumab and irinotecan therapy. Patients and Methods: In a phase II trial, 60 patients with recurrent malignant astrocytomas were treated with bevacizumab and irinotecan. Tumor specimens collected at the time of diagnosis were available for further pathologic studies in 45 patients (75%). VEGF, VEGF receptor-2, CD31, hypoxia-inducible carbonic anhydrase 9 (CA9), and hypoxia-inducible factor-2α were semiquantitatively assessed by immunohistochemistry. Radiographic response and survival outcomes were correlated with these angiogenic and hypoxic markers. Results: Of 45 patients, 27 patients had glioblastoma multiforme, and 18 patients had anaplastic astrocytoma. Twenty-six patients (58%) had at least partial radiographic response. High VEGF expression was associated with increased likelihood of radiographic response (P = .024) but not survival benefit. Survival analysis revealed that high CA9 expression was associated with poor survival outcome (P = .016). Conclusion: In this patient cohort, tumor expression levels of VEGF, the molecular target of bevacizumab, were associated with radiographic response, and the upstream promoter of angiogenesis, hypoxia, determined survival outcome, as measured from treatment initiation. Validation in a larger clinical trial is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Hypoxia signalling in cancer and approaches to enforce tumour regression
Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676
Cairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.19.1473 · Cited by 1,610
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., & Batchelor, T. T. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2175 · Cited by 1,405
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,394
Self-citationDifferential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation
Hu, C.-J., Wang, L.-Y., Chodosh, L. A., Keith, B., & Simon, M. C. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.9361-9374.2003 · Cited by 1,386
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2309 · Cited by 1,078
Self-citationOutcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902 · cited 1×
“Although bevacizumab and irinotecan have a more prominent efficacy in patients with low CA9expressing tumors, this therapy still offers survival benefit, albeit modest, in patients with high CA9 expression (median survival time, 37 weeks) when compared with the survival of recurrent or progressive glioma patients trea…”
BackgroundHypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis
Kaur, B., Khwaja, F. W., Severson, E. A., Matheny, S. L., Brat, D. J., & Van Meir, E. G. (2005) · Neuro-Oncology · doi:10.1215/s1152851704001115 · Cited by 725 · cited 1×
“Hypoxia is one of the key pathophysiologic features in glioblastomas driving angiogenesis, invasion, and therapeutic resistance.(7,8) Carbonic anhydrase 9 (CA9) is a hypoxiainducible transmembrane enzyme that has recently been shown to be an independent prognostic factor for malignant astrocytoma patients.”
BackgroundRegulation of tumor pH and the role of carbonic anhydrase 9
Swietach, P., Vaughan-Jones, R. D., & Harris, A. L. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9064-0 · Cited by 539 · cited 1×
“CA9 has been shown to be an independent prognostic marker in patients with various cancers including malignant gliomas.(9-11,29,30) Although bevacizumab and irinotecan have a more prominent efficacy in patients with low CA9expressing tumors, this therapy still offers survival benefit, albeit modest, in patients with h…”
BackgroundEpidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji161 · Cited by 465
Sowter, H., Raval, R. R., Moore, J. W., Ratcliffe, P. J., & Harris, A. L. (2003) · PubMed · Cited by 416
Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer
Atkins, M. B., Regan, M. M., McDermott, D. F., Mier, J. W., Stanbridge, E. J., Youmans, A. J., Febbo, P. G., Upton, M. P., Lechpammer, M., & Signoretti, S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2019 · Cited by 402
Jubb, A. M., Hurwitz, H. I., Bai, W., Holmgren, E. B., Tobin, P., Guerrero, A. S., Kabbinavar, F., Holden, S. N., Novotny, W. F., Frantz, G. D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5388 · Cited by 387
Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma
Friedman, H. S., Petros, W. P., Friedman, A. H., Schaaf, L. J., Kerby, T., Lawyer, J., Parry, M., Houghton, P. J., Lovell, S., Rasheed, K., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1516 · Cited by 357
Self-citationKoukourakis, M. I., Bentzen, S. M., Giatromanolaki, A., Wilson, G. D., Daley, F. M., Saunders, M. I., Dische, S., Sivridis, E., & Harris, A. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7474 · Cited by 289
Potter, C., & Harris, A. L. (2004) · Cell Cycle · doi:10.4161/cc.3.2.618 · Cited by 279
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Pope, W. B., Lai, A., Nghiemphu, P., Mischel, P., & Cloughesy, T. F. (2006) · Neurology · doi:10.1212/01.wnl.0000208958.29600.87 · Cited by 271
(2003) · PubMed · Cited by 269
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Chamberlain, M. C. (2006) · Neurology · doi:10.1212/01.wnl.0000250628.10420.d8 · Cited by 264
Prados, M. D., Lamborn, K., Yung, W. K. A., Jaeckle, K., Robins, H. I., Mehta, M., Fine, H. A., Wen, P. Y., Cloughesy, T., Chang, S., et al. (2006) · Neuro-Oncology · doi:10.1215/15228517-2005-010 · Cited by 254
Predicting benefit from anti-angiogenic agents in malignancy
Jubb, A. M., Oates, A. J., Holden, S., & Koeppen, H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1946 · Cited by 228
Prados, M. D., Lamborn, K. R., Chang, S., Burton, E., Butowski, N., Malec, M., Kapadia, A., Rabbitt, J., Page, M. S., Fedoroff, A., et al. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000451 · Cited by 218
Carson, K. A., Grossman, S. A., Fisher, J. D., & Shaw, E. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1661 · Cited by 205
Expression of Carbonic Anhydrase IX in Astrocytic Tumors Predicts Poor Prognosis
Haapasalo, J. A., Nordfors, K., Hilvo, M., Rantala, I., Soini, Y., Parkkila, A., Pastoreková, S., Pastorek, J., Parkkila, S., & Haapasalo, H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0848 · Cited by 134
Batchelor, T. T., Gilbert, M. R., Supko, J. G., Carson, K. A., Nabors, B., Grossman, S. A., Lesser, G. J., Mikkelsen, T., & Phuphanich, S. (2004) · Neuro-Oncology · doi:10.1215/s1152851703000218 · Cited by 114
Cao, Y., Sonveaux, P., Liu, S., Zhao, Y., Mi, J., Clary, B. M., Li, C., Kontos, C. D., & Dewhirst, M. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4056 · Cited by 101
Self-citationKorkolopoulou, P. A., Perdiki, Μ., Thymara, I., Boviatsis, E. I., Agrogiannis, G. D., Kotsiakis, X., Angelidakis, D., Rologis, D., Diamantopoulou, K., Thomas-Tsagli, E., et al. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.07.020 · Cited by 51
Serganova, I., Humm, J., Ling, C., & Blasberg, R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0517 · Cited by 50
Using molecular information to guide brain tumor therapy
Mischel, P. S., & Cloughesy, T. F. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0145 · Cited by 17
Cited by
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
“One recent study suggests that hypoxia determines survival outcome in bevacizumab-treated GBM patient”
BackgroundHypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells
Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., Shi, Q., Cao, Y., Lathia, J., McLendon, R. E., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.018 · Cited by 1,354
Self-citationGlioblastoma multiforme: a review of where we have been and where we are going
Adamson, C., Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Mattox, A. K., & Bigner, D. D. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903052764 · Cited by 550
Targeting Macrophages in Cancer: From Bench to Bedside
Poh, A. R., & Ernst, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00049 · Cited by 501
Metadata
- Authors
- Sathornsumetee, S., Cao, Y., Marcello, J. E., Herndon, J. E., McLendon, R. E., Desjardins, A., Friedman, H. S., Dewhirst, M. W., Vredenburgh, J. J., & Rich, J. N.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-01-10
- Volume
- 26
- Issue
- 2
- Pages
- 271-278
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2020021293
- Cited by
- 261
- References
- 33
- FWCI
- 14.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.